TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03420196

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised exercise program
Description: It will consist in a supervised exercise program, including the following exercises:~* Diaphragmatic breathing.~* Transverse abdomLateral leg raise for gluteus mediuminis muscle activation.~* Pelvic swing.~* Gluteus bridge.~* Spinal mobility.~* Spinal extensor muscles strengthening~* Frontal plank~* Side plank.~* Lateral leg raise for gluteus medium

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non supervised exercise program
Description: It will consist in a non supervised exercise program, including the following exercises:~* Diaphragmatic breathing.~* Transverse abdomLateral leg raise for gluteus mediuminis muscle activation.~* Pelvic swing.~* Gluteus bridge.~* Spinal mobility.~* Spinal extensor muscles strengthening~* Frontal plank~* Side plank.~* Lateral leg raise for gluteus medium
Study: NCT03479411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole Powder
Description: Itraconazole administered as a dry powder for inhalation (PUR1900)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole Powder
Description: Itraconazole administered as a dry powder for inhalation (PUR1900)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itraconazole Powder
Description: Itraconazole administered as a dry powder for inhalation (PUR1900)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itraconazole 200 mg
Description: Sporanox® Oral Solution
Study: NCT02084420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaprazole
Description: 10mg 2 BID( 2 times / day), before breakfast and dinner

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: 40mg, BID(2 times / day), before breakfast and dinner
Study: NCT01816672

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AutoloGel
Description: Treatment with Autologel and standard of care twice a week for the first two weeks and once a week thereafter

Intervention type: OTHER
Group type: OTHER
Intervention: Usual and Customary Care
Description: Standard of care treatment twice weekly for 2 weeks then weekly
Study: NCT05369936

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aromatherapy
Description: Lavender will be inhaled through three phases

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vapors of the distal water will be inhaled through three phases
Study: NCT01854385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg
Description: This is a single-arm, unblinded study of treatment for post-traumatic headache with the open label medication sumatriptan and is being undertaken to test necessary study instruments and procedures, establish feasibility and determine side effects in a population with complicated mild, moderate and severe TBI.
Study: NCT04570072

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Patients receive the formula probiotic for consecutive 8 weeks ( one sachet per day ).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receive the placebo identical to probiotic for consecutive 8 weeks ( one sachet per day ).
Study: NCT03706521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM04690
Description: Healthcare professional-administered intra-articular injection performed once on Day 1 of the study.
Study: NCT03980613

Intervention type: OTHER
Intervention: Triage
Description: Emergency telephone calls from cases and controls are replayed and analyzed for symptom descriptions indicating spontaneous subarachnoid haemorrhage.
Study: NCT03537716

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment with High Intensity Focused ElectroMagnetic system
Description: The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the abdomen area. Visible contractions will be induced by the device.
Study: NCT02297698

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeuVax vaccine
Description: At the time of vaccine administration, a frozen solution of E75 acetate (1.5 mg/mL) is thawed and 1000mcg E75 peptide mixed thoroughly with 250mcg GM-CSF. This constitutes the NeuVax vaccine. Patients randomized to this arm will receive vaccinations of nelipepimut-S/GM-CSF administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of trastuzumab infusion. The first vaccination will be given with the third dose of maintenance trastuzumab administered as monotherapy optimally, but may be given with later maintenance doses of trastuzumab, provided there are at least six remaining doses of trastuzumab to overlap with the primary vaccine series.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Herceptin will be administered to patients every three weeks as monotherapy for one year, to be given upon completion of standard of care chemotherapy/radiotherapy. The first trastuzumab infusion will be given no sooner than three weeks and no later than 12 weeks after completion of chemotherapy/radiotherapy. Trastuzumab will be dosed at the recommended initial loading dose of 8 mg/kg and at recommended maintenance doses of 6 mg/kg q3wk.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Herceptin will be administered to patients every three weeks as monotherapy for one year, to be given upon completion of standard of care chemotherapy/radiotherapy. The first trastuzumab infusion will be given no sooner than three weeks and no later than 12 weeks after completion of chemotherapy/radiotherapy. Trastuzumab will be dosed at the recommended initial loading dose of 8 mg/kg and at recommended maintenance doses of 6 mg/kg q3wk.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GM-CSF
Description: For patients randomized to the GM-CSF alone arm, they will receive inoculations of GM-CSF (250mcg) administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of trastuzumab infusion. The first injection will be given with the third dose of maintenance trastuzumab administered as monotherapy optimally, but may be given with later maintenance doses of trastuzumab, provided there are at least six remaining doses of trastuzumab to overlap with the primary vaccine series.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: For patients randomized to the GM-CSF alone arm, they will receive inoculations of GM-CSF (250mcg) administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of trastuzumab infusion. The first injection will be given with the third dose of maintenance trastuzumab administered as monotherapy optimally, but may be given with later maintenance doses of trastuzumab, provided there are at least six remaining doses of trastuzumab to overlap with the primary vaccine series.
Study: NCT04332965

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-Surgical Periodontal Treatment
Description: Scaling and root planing and polishing with specific curettes were performed to patients and oral hygiene education was provided to each patient.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-Surgical Periodontal Treatment
Description: Scaling and root planing and polishing with specific curettes were performed to patients and oral hygiene education was provided to each patient.
Study: NCT00891917

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ubiquinol-10 Syrup
Description: 10 mg/kg/day in 2 divided doses for 3 months or Placebo Syrup for 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: syrup (placebo)
Description: syrup looks exactly like the Ubiquinol-10 Syrup but has no active ingredients or supplementation
Study: NCT00465465

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA 85A
Description: i.d. injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA 85A
Description: i.d. injection
Study: NCT04602975

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection SF2A-TT15 10 µg Adjuvanted
Description: Intramuscular injection of experimental vaccine (adjuvanted 10 µg)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection SF2A-TT15 10 µg Adjuvanted
Description: Intramuscular injection of experimental vaccine (adjuvanted 10 µg)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection SF2A-TT15 10 µg Adjuvanted
Description: Intramuscular injection of experimental vaccine (adjuvanted 10 µg)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection SF2A-TT15 10 µg
Description: Intramuscular injection of experimental vaccine (not adjuvanted 10 µg)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Injection Adjuvanted Placebo
Description: Intramuscular injection of Placebo with alhydrogel

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Injection Adjuvanted Placebo
Description: Intramuscular injection of Placebo with alhydrogel

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Injection Adjuvanted Placebo
Description: Intramuscular injection of Placebo with alhydrogel

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Injection Adjuvanted Placebo
Description: Intramuscular injection of Placebo with alhydrogel

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Injection Placebo
Description: Intramuscular injection of the not adjuvanted Placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Injection Placebo
Description: Intramuscular injection of the not adjuvanted Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection SF2A-TT15 2 µg Adjuvanted
Description: Intramuscular injection of experimental vaccine (adjuvanted 2 µg)
Study: NCT02732119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: supplied in 2.5 mg tablets taken orally, daily for 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: supplied in 25 mg tablets taken orally, daily for 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: supplied in 25 mg tablets taken orally, daily for 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: supplied in 25 mg tablets taken orally, daily for 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: supplied in 25 mg tablets taken orally, daily for 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: supplied in 25 mg tablets taken orally, daily for 28 day cycle
Study: NCT02648776

Intervention type: DRUG
Intervention: Exposure to sedative-hypnotic drugs
Description: These patients will have been prescribed a sedative-hypnotic drug for at least one week prior to enrollment.

Intervention type: DRUG
Intervention: Exposure to sedative-hypnotic drugs
Description: These patients will have been prescribed a sedative-hypnotic drug for at least one week prior to enrollment.

Intervention type: DRUG
Intervention: Exposure to sedative-hypnotic drugs
Description: These patients will have been prescribed a sedative-hypnotic drug for at least one week prior to enrollment.

Intervention type: DRUG
Intervention: Exposure to sedative-hypnotic drugs
Description: These patients will have been prescribed a sedative-hypnotic drug for at least one week prior to enrollment.

Intervention type: DRUG
Intervention: Exposure to sedative-hypnotic drugs
Description: These patients will have been prescribed a sedative-hypnotic drug for at least one week prior to enrollment.

Intervention type: DRUG
Intervention: Exposure to sedative-hypnotic drugs
Description: These patients will have been prescribed a sedative-hypnotic drug for at least one week prior to enrollment.

Intervention type: DRUG
Intervention: Exposure to sedative-hypnotic drugs
Description: These patients will have been prescribed a sedative-hypnotic drug for at least one week prior to enrollment.
Study: NCT03733002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AngongNiuhuang pill
Description: This group will receive AngongNiuhuang pill 1 pill 1 times/day for 5-day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of AngongNiuhuang pill
Description: This group will receive Placebo of AngongNiuhuang pill 1 pill 1 times/day for 5-day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment
Description: The other treatments according to guidelines for standard treatment of acute ischemic stroke.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard treatment
Description: The other treatments according to guidelines for standard treatment of acute ischemic stroke.
Study: NCT03719521

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Community-based package of integrated HIV, SRH and general health services
Description: HIV Testing and Counselling, SRH and HIV prevention Services and General Health Counselling for all 16-24 year olds and ART initiation and ongoing treatment and adherence support for those who test HIV positive

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community-based package of integrated HIV, SRH and general health services
Description: HIV Testing and Counselling, SRH and HIV prevention Services and General Health Counselling for all 16-24 year olds and ART initiation and ongoing treatment and adherence support for those who test HIV positive
Study: NCT02468115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIS410
Description: Single fixed IV dose of VIS410

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single IV dose of placebo
Study: NCT00679315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alfuzosin hydrochloride XL 10mg
Description: One tablet to be taken daily after a meal before bedtime for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet to be taken daily after a meal before bedtime for 8 weeks.
Study: NCT00964860

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glide dental floss
Description: Glide waxed dental floss
Study: NCT01612481

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: chest radiography
Description: surveillance by radiography of chest every 3 months the first 2 years then every 6 month the third, forth and fifth years

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: chest CT
Description: surveillance by CT of chest every 3 months the first 2 years then every 6 month the third, forth and fifth years
Study: NCT00736684

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Proximal Femoral Nail AntirotationTM (PFNA)
Description: intramedullary nailing

Intervention type: DEVICE
Group type: OTHER
Intervention: Gamma Nail 3TM (Gamma3)
Description: intramedullary nailing
Study: NCT04602975

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection SF2A-TT15 2 µg
Description: Intramuscular injection of experimental vaccine (not adjuvanted 2 µg)
Study: NCT01154192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Each subject in each group will receive 1 mg of oral dexamethasone in the evening and return in the morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will also have blood drawn at times -0.5, 0, 0.5, and 24 hours after the injection of r-hCG for measurement of steroid hormones.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Each subject in each group will receive 1 mg of oral dexamethasone in the evening and return in the morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will also have blood drawn at times -0.5, 0, 0.5, and 24 hours after the injection of r-hCG for measurement of steroid hormones.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Each subject in each group will receive 1 mg of oral dexamethasone in the evening and return in the morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will also have blood drawn at times -0.5, 0, 0.5, and 24 hours after the injection of r-hCG for measurement of steroid hormones.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human chorionic gonadotropin (r-hCG)
Description: Each subject in each group will receive 1 mg of oral dexamethasone in the evening and return in the morning for an injection of 25ug of IV recombinant human chorionic gonadotropin (r-hCG). Subjects will also have blood drawn at times -0.5, 0, 0.5, and 24 hours after the injection of r-hCG for measurement of steroid hormones.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human chorionic gonadotropin (r-hCG)
Description: Each subject in each group will receive 1 mg of oral dexamethasone in the evening and return in the morning for an injection of 25ug of IV recombinant human chorionic gonadotropin (r-hCG). Subjects will also have blood drawn at times -0.5, 0, 0.5, and 24 hours after the injection of r-hCG for measurement of steroid hormones.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human chorionic gonadotropin (r-hCG)
Description: Each subject in each group will receive 1 mg of oral dexamethasone in the evening and return in the morning for an injection of 25ug of IV recombinant human chorionic gonadotropin (r-hCG). Subjects will also have blood drawn at times -0.5, 0, 0.5, and 24 hours after the injection of r-hCG for measurement of steroid hormones.
Study: NCT00733811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone (DFP) and Deferoxamine (DFO)
Description: Sequential treatment including DFP at 75 mg/kg for four days per week and DFO by subcutaneous infusions (8-12h) at 50mg/kg/day for the remaining three days per week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferiprone (DFP)
Description: DFP alone at 75 mg/kg divided into three oral daily doses
Study: NCT01910012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-PEG 20
Study: NCT02637661

Intervention type: OTHER
Intervention: earlobe crease positive

Intervention type: OTHER
Intervention: earlobe crease positive

Intervention type: OTHER
Intervention: earlobe crease negative

Intervention type: OTHER
Intervention: earlobe crease negative
Study: NCT00837473

Intervention type: DEVICE
Group type: OTHER
Intervention: Plexur-P used as a Bone Void Filler in Iliac Crest Harvesting Procedures
Description: Plexur-P used as a Bone Void Filler in Iliac Crest Harvesting Procedures
Study: NCT04610879

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbamazepine
Description: Treatment will be procured, prescribed and issued as per routine NHS practice. Generics can be prescribed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbamazepine
Description: Treatment will be procured, prescribed and issued as per routine NHS practice. Generics can be prescribed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam
Description: Treatment will be procured, prescribed and issued as per routine NHS practice. Generics can be prescribed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam
Description: Treatment will be procured, prescribed and issued as per routine NHS practice. Generics can be prescribed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent based sleep (PBS) intervention
Description: The PBS intervention is an e-learning package for parents/primary carers and children with epilepsy. The PBS intervention offers parents education about normal sleep, advice about sleep-promoting practices and targeted strategies parents can employ to help their children to ''learn'' an appropriate set of sleep behaviours/habits and/or to unlearn inappropriate sleep behaviours.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent based sleep (PBS) intervention
Description: The PBS intervention is an e-learning package for parents/primary carers and children with epilepsy. The PBS intervention offers parents education about normal sleep, advice about sleep-promoting practices and targeted strategies parents can employ to help their children to ''learn'' an appropriate set of sleep behaviours/habits and/or to unlearn inappropriate sleep behaviours.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent based sleep (PBS) intervention
Description: The PBS intervention is an e-learning package for parents/primary carers and children with epilepsy. The PBS intervention offers parents education about normal sleep, advice about sleep-promoting practices and targeted strategies parents can employ to help their children to ''learn'' an appropriate set of sleep behaviours/habits and/or to unlearn inappropriate sleep behaviours.
Study: NCT01444118

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Therapeutic EGF Vaccine (Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine)
Description: Patients in this arm will receive a low dose of Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine in addition to Best Supportive Care.
Study: NCT00641459

Intervention type: OTHER
Intervention: Observational BPSD treatment study
Description: Observational BPSD treatment study
Study: NCT02985684

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GORE® CARDIOFORM ASD Occluder
Description: Percutaneous Atrial Septal Defect Closure
Study: NCT06063525

Intervention type: OTHER
Intervention: Structural anatomy
Description: images acquired with 3T MRI system with 32 channel head coil
Study: NCT02594085

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patch 6
Description: Patch 6 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 6 contains buffer with filler. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patch 6
Description: Patch 6 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 6 contains buffer with filler. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patch 6
Description: Patch 6 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 6 contains buffer with filler. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
Study: NCT06063525

Intervention type: OTHER
Intervention: Structural anatomy
Description: images acquired with 3T MRI system with 32 channel head coil

Intervention type: OTHER
Intervention: Structural anatomy
Description: images acquired with 3T MRI system with 32 channel head coil